K-ras mutations and prognosis in large-bowel carcinomas

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 1, 1997, Pages 62-69

  Norheim Andersen, S ^a   Lovig T ^b   Breivik, J ^b   Lund, E ^b   Gaudernack, G ^b   Meling, G I ^b   Rognum, T O ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Adenocarcinoma; Colorectal neoplasms; Genes, K ras; Polymerase chain reaction; Restriction fragment length polymorphism; Survival

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL;

EID: 0031013496     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709025065     Document Type: Article

References (37)

1. Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958;12:309-20.
2. Turnbull RB, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technique on survival rates. Ann Surg 1967;166:420-7.
3. Remmele W, Heine M. Pathologisch-anatomische Begutachtung Kolorektaler Karzinome unter prognostischen Gesichtspunkten. Med Welt 1981;32:771-7.
4. Wanebo HJ, Rao B, Pinsky CM, Hoffmann RG, Stearns M, Schwartz MK, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978;299:448-51.
5. Rognum TO. A new approach in carcinoembryonic antigen-guided follow-up of large-bowel carcinoma patients. Scand J Gastroenterol 1986;21:641-9.
6. Meling GI, Rognum TO, Clausen OPF, Børmer O, Lunde OC, Schlichting E, et al. Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients. Scand J Gastroenterol 1992;27: 1061-8.
7. Wolley RC, Schreiber K, Koss LG, Karas M, Sherman A. DNA distribution in human colon carcinomas and its relationship to clinical behaviour. J Natl Cancer Inst 1982;69:15-22.
8. Rognum TO, Thorud E, Lund E. Survival of large bowel carcinoma patients with different DNA ploidy. Br J Cancer 1987;56:633-6.
9. Rognum TO, Lund E, Meling GI, Langmark F. Near diploid large bowel carcinomas have better five-year survival than aneuploid ones. Cancer 1991;68:1077-81.
10. Norheim Andersen S, Rognum TO, Lund E, Meling GI, Hauge S. Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993;68:80-5.
11. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
12. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298-303.
13. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
14. Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci USA 1989;86:2403-7.
15. McLellan EA, Owen RA, Stepniewska KA, Sheffield JP, Lemoine NR. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut 1993;34:392-6.
16. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992;52:30-3.
17. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71:3827-38.
18. Finkelstein SD, Sayegh R, Bakker A, Swaksky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-32.
19. Benhattar J, Losi L, Chaubert P, Givel J-C, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
20. Moerkerk P, Arends JW, van Driel M, de Bruïne A, de Goeij A, ten Kate J. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994;54:3376-8.
21. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 1994;69:367-71.
22. Ashley DJB. Evans' histological appearance of tumours. 3rd ed. Edinburgh: Livingstone, 1978:582-7.
23. Rognum TO, Heier HE, Ørjasaeter H, Thorud E, Brandtzaeg P. Comparison of two CEA assays in primary and recurrent large bowel carcinoma with different DNA ploidy pattern. Eur J Clin Oncol 1986;22:1165-9.
24. Brandtzaeg P. Mucosal and glandular distribution of immunoglobulin components. Immunohistochemistry with a cold ethanol-fixation technique. Immunology 1974;26:1101-14.
25. Kahn SM, Jiang W, Culbertson TA, Weinstein B, Williams GM, Tomita N, et al. Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 1991;6:1079-83.
26. Norheim Andersen S, Breivik J, Løvig T, Meling GI, Gaudernack G, Clausen OPF, et al. K-ras mutations and HLA-DR expression in large bowel adenomas. Br J Cancer 1446;74: 99-108.
27. Sanger F, Niclen S, Coulsen AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 1977;74: 5463-7.
28. Cox D. Regression models and life tables. J Royal Stat Soc (B) 1972;34:187-200.
29. Shibata D, Schaeffer J, Li Z-H, Capella G, Perucho M. Genetic-heterogeneity of the c-K-ras locus in colorectal adenomas hut not in adenocarcinomas. J Natl Cancer Inst 1993;85:1058-63.
30. Soh K, Yanagisawa A, Hiratsuka H, Sugano H, Kato Y. Variation in K-ras codon 12 point mutation rate with histological atypia within individual colorectal tumors. Jpn J Cancer Res 1993;84:388-93.
31. Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992;28A:1115-20.
32. Kastrinakis WV, Ramchurren N, Maggard M, Steele G Jr, Summerhayes IC. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995;130:9-14.
33. Pricolo VE, Finkelstein SD, Wu T-T, Keller G, Bakker A, Swalsky PA, et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:41-6.
34. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and aquired genetic alterations in colorectal cancer. Gastroenterology 1992;102: 1136-41.
35. Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I. Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 1994;57:57-64.
36. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ, The General Surgeons at Sir Charles Gairdner Hospital. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994;59:747-51.
37. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.